Trial of Artesunate and Sulfadoxine-Pyrimethamine for Malaria Control
Author Information
Author(s): El-Sayed Badria, El-Zaki Salah-Eldin, Babiker Hamza, Gadalla Nahla, Ageep Tellal, Mansour Fathi, Baraka Omer, Milligan Paul, Babiker Ahmed
Primary Institution: Department of Epidemiology, Tropical Medicine Research Institute, National Centre for Research, Khartoum, Sudan
Hypothesis
Does the addition of primaquine improve the elimination of low-density P. falciparum parasitaemia and gametocyte carriage?
Conclusion
Adding primaquine to artemisinin combination treatment did not enhance the elimination of parasitaemia or prevent gametocyte carriage in low-density carriers during the dry season.
Supporting Evidence
- The study enrolled 104 individuals with low-density P. falciparum infection.
- On day 7, 8.3% were positive by PCR in the AS+SP+PQ group and 6.5% in the AS+SP group.
- At enrolment, 12% of participants were carrying gametocytes, which was reduced by day 14.
Takeaway
The study tested two treatments for malaria and found that one treatment worked just as well without an extra drug, which means we can use the simpler option to help control malaria.
Methodology
A two-arm open-label randomized controlled trial was conducted with participants receiving either AS+SP or AS+SP+PQ, with outcomes measured by PCR and RT-PCR.
Potential Biases
The trial was not blinded, which may introduce bias in the results.
Limitations
The study's power to detect an effect of primaquine on gametocyte carriage was limited, and the sensitivity of the PCR used may have affected results.
Participant Demographics
Participants included asymptomatic adults and children over 6 months from two villages in eastern Sudan, with a mean age of 21.9 years.
Statistical Information
P-Value
0.315
Confidence Interval
95%CI −10.3% to +13.8%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website